PP
TNGX icon

PDT Partners’s Tango Therapeutics TNGX Stock Holding History

PDT Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-102,807
Closed -$318K – 854
2024
Q4 		$318K Buy
+102,807
New +$477K 0.03% 568
2023
Q3 		– Sell
-13,989
Closed -$46.4K – 683
2023
Q2 		$46.4K Buy
+13,989
New +$50.3K 0.01% 548

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PDT Partners's TNGX Position: Q1 2025 in Review

PDT Partners sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 102,807 shares — an estimated $318K sold.

PDT Partners first reported a position in TNGX in Q2 2023 and held it in 2 quarters. The position peaked at $318K in Q4 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • PDT Partners reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 102,807 Tango Therapeutics shares in Q1 2025, an estimated $318K.
  • PDT Partners first reported a position in Tango Therapeutics in Q2 2023 and held it in 2 quarters.
  • PDT Partners's Tango Therapeutics position peaked at $318K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.